Concepedia

Kate Liu

KL

Statistics

Publications

3

Citations

230

H-Index

3

Active since

2012

Affiliations

Amgen (United States)(Current)

Kate Liu is an author at Amgen (United States) specializing in immunotherapy, oncology, and melanoma immunotherapy.

Publications per year

2012–2021

3

Publications

3

Sulfonyl Fluoride‐Based Prosthetic Compounds as Potential <sup>18</sup>F Labelling Agents

James A. H. Inkster, Kate Liu, Samia Aı̈t-Mohand et al. · Chemistry - A European Journal · 2012 · 83 citations

, , +12

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

Josep Malvehy, Igor Samoylenko, Dirk Schadendorf et al. · Journal for ImmunoTherapy of Cancer · 2021 · 79 citations · Full text

, , +17

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis et al. · EBioMedicine · 2019 · 68 citations · Full text

, , +16

1–3 of 3